NewAmsterdam Pharma (NAMS) Shares Outstanding (Weighted Average) (2021 - 2026)

NewAmsterdam Pharma has disclosed Shares Outstanding (Weighted Average) across 6 years of filings, most recently posting $121.7 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $121.7 million, up 4.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $121.7 million (up 4.81% YoY), and the FY2025 annual result was $118.4 million, up 25.51% from the prior year.
• Shares Outstanding (Weighted Average) came in at $121.7 million for Q1 2026 at NewAmsterdam Pharma, up from $118.4 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $121.7 million in Q1 2026 to a low of $19.4 million in Q4 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $94.5 million (2024), against an average of $93.8 million.
• Across the five-year window, Shares Outstanding (Weighted Average) tumbled 79.83% in 2022 and soared 324.6% in 2023, its largest moves.
• NewAmsterdam Pharma's Shares Outstanding (Weighted Average) stood at $19.4 million in 2022, then soared by 324.6% to $82.2 million in 2023, then rose by 14.84% to $94.4 million in 2024, then rose by 25.51% to $118.4 million in 2025, then advanced by 2.78% to $121.7 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $121.7 million (Q1 2026), $118.4 million (Q4 2025), and $119.0 million (Q3 2025), per Business Quant data.